Cargando…
CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model
Large cell lung carcinoma (LCLC) is one form of NSCLC that spreads more aggressively than some other forms, and it represents an unmet medical need. Here, we investigated for the first time the effect of the anti-CK2 CIGB-300 peptide in NCI-H460 cells as an LCLC model. NCI-H460 cells were highly sen...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856093/ https://www.ncbi.nlm.nih.gov/pubmed/36672551 http://dx.doi.org/10.3390/biomedicines11010043 |
_version_ | 1784873538479456256 |
---|---|
author | Pérez, George V. Rosales, Mauro Ramón, Ailyn C. Rodríguez-Ulloa, Arielis Besada, Vladimir González, Luis J. Aguilar, Daylen Vázquez-Blomquist, Dania Falcón, Viviana Caballero, Evelin Carvalho, Paulo C. Caldeira, Rodrigo Soares Yang, Ke Perera, Yasser Perea, Silvio E. |
author_facet | Pérez, George V. Rosales, Mauro Ramón, Ailyn C. Rodríguez-Ulloa, Arielis Besada, Vladimir González, Luis J. Aguilar, Daylen Vázquez-Blomquist, Dania Falcón, Viviana Caballero, Evelin Carvalho, Paulo C. Caldeira, Rodrigo Soares Yang, Ke Perera, Yasser Perea, Silvio E. |
author_sort | Pérez, George V. |
collection | PubMed |
description | Large cell lung carcinoma (LCLC) is one form of NSCLC that spreads more aggressively than some other forms, and it represents an unmet medical need. Here, we investigated for the first time the effect of the anti-CK2 CIGB-300 peptide in NCI-H460 cells as an LCLC model. NCI-H460 cells were highly sensitive toward CIGB-300 cytotoxicity, reaching a peak of apoptosis at 6 h. Moreover, CIGB-300 slightly impaired the cell cycle of NCI-H460 cells. The CIGB-300 interactomics profile revealed in more than 300 proteins that many of them participated in biological processes relevant in cancer. Interrogation of the CK2 subunits targeting by CIGB-300 indicated the higher binding of the peptide to the CK2α′ catalytic subunit by in vivo pull-down assays plus immunoblotting analysis and confocal microscopy. The down-regulation of both phosphorylation and protein levels of the ribonuclear protein S6 (RPS6) was observed 48 h post treatment. Altogether, we have found that NCI-H460 cells are the most CIGB-300-sensitive solid tumor cell line described so far, and also, the findings we provide here uncover novel features linked to CK2 targeting by the CIGB-300 anticancer peptide. |
format | Online Article Text |
id | pubmed-9856093 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98560932023-01-21 CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model Pérez, George V. Rosales, Mauro Ramón, Ailyn C. Rodríguez-Ulloa, Arielis Besada, Vladimir González, Luis J. Aguilar, Daylen Vázquez-Blomquist, Dania Falcón, Viviana Caballero, Evelin Carvalho, Paulo C. Caldeira, Rodrigo Soares Yang, Ke Perera, Yasser Perea, Silvio E. Biomedicines Article Large cell lung carcinoma (LCLC) is one form of NSCLC that spreads more aggressively than some other forms, and it represents an unmet medical need. Here, we investigated for the first time the effect of the anti-CK2 CIGB-300 peptide in NCI-H460 cells as an LCLC model. NCI-H460 cells were highly sensitive toward CIGB-300 cytotoxicity, reaching a peak of apoptosis at 6 h. Moreover, CIGB-300 slightly impaired the cell cycle of NCI-H460 cells. The CIGB-300 interactomics profile revealed in more than 300 proteins that many of them participated in biological processes relevant in cancer. Interrogation of the CK2 subunits targeting by CIGB-300 indicated the higher binding of the peptide to the CK2α′ catalytic subunit by in vivo pull-down assays plus immunoblotting analysis and confocal microscopy. The down-regulation of both phosphorylation and protein levels of the ribonuclear protein S6 (RPS6) was observed 48 h post treatment. Altogether, we have found that NCI-H460 cells are the most CIGB-300-sensitive solid tumor cell line described so far, and also, the findings we provide here uncover novel features linked to CK2 targeting by the CIGB-300 anticancer peptide. MDPI 2022-12-25 /pmc/articles/PMC9856093/ /pubmed/36672551 http://dx.doi.org/10.3390/biomedicines11010043 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Pérez, George V. Rosales, Mauro Ramón, Ailyn C. Rodríguez-Ulloa, Arielis Besada, Vladimir González, Luis J. Aguilar, Daylen Vázquez-Blomquist, Dania Falcón, Viviana Caballero, Evelin Carvalho, Paulo C. Caldeira, Rodrigo Soares Yang, Ke Perera, Yasser Perea, Silvio E. CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model |
title | CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model |
title_full | CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model |
title_fullStr | CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model |
title_full_unstemmed | CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model |
title_short | CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model |
title_sort | cigb-300 anticancer peptide differentially interacts with ck2 subunits and regulates specific signaling mediators in a highly sensitive large cell lung carcinoma cell model |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856093/ https://www.ncbi.nlm.nih.gov/pubmed/36672551 http://dx.doi.org/10.3390/biomedicines11010043 |
work_keys_str_mv | AT perezgeorgev cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel AT rosalesmauro cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel AT ramonailync cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel AT rodriguezulloaarielis cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel AT besadavladimir cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel AT gonzalezluisj cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel AT aguilardaylen cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel AT vazquezblomquistdania cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel AT falconviviana cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel AT caballeroevelin cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel AT carvalhopauloc cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel AT caldeirarodrigosoares cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel AT yangke cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel AT pererayasser cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel AT pereasilvioe cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel |